IMUX实时信号 | 通过Getagraph.com最大化利润

购买 107665 min ago

@ $1.320

发出时间: 15 Feb 2024 @ 04:57

回报率: -3.90%

上一信号: Feb 9 - 22:39

上一信号: 出售

回报率: 4.35 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 23:19):

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases...

Stats
今日成交量	62 022.00
平均成交量	536 353
市值	114.07M
EPS	$0 ( 2024-02-22 )
下一个收益日期	( $-0.270 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.600
ATR14	$0.00600 (0.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Howson Tamar D	Buy	64 959	Stock Option
2024-03-04	Howson Tamar D	Sell	10 000	Stock Option
2024-03-04	Howson Tamar D	Sell	10 000	Stock Option
2024-03-04	Howson Tamar D	Sell	9 986	Stock Option
2024-03-04	Howson Tamar D	Sell	15 000	Stock Option

INSIDER POWER
44.54
Last 97 transactions
Buy: 5 390 136 \| Sell: 1 509 904

音量相关性

長: 0.02 (neutral)

短: 0.00 (neutral)

Signal:(58.531) Neutral

Immunic Inc 相关性

10 最正相关
TOP	0.913
HOWL	0.902
BNIXU	0.887
GAINL	0.884
OLMA	0.874
IPKW	0.873
EOLS	0.87
ALGS	0.867
LILAK	0.867
ISNS	0.866

10 最负相关
MMAC	-0.89
BOCH	-0.886
SHSP	-0.857
PEP	-0.832
NETE	-0.826
AMRB	-0.825

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Immunic Inc 相关性 - 货币/商品

-0.84
( strong negative )

-0.22
( neutral )

0.00
( neutral )

0.57
( weak )

Immunic Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-111 000 (0.00 %)
EPS:	$-2.11

FY	2023
营收:	$0
毛利润:	$-111 000 (0.00 %)
EPS:	$-2.11

FY	2022
营收:	$0
毛利润:	$-77 000.00 (0.00 %)
EPS:	$-4.85

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-3.93

Financial Reports:

No articles found.

Immunic Inc

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.